Femtobiomed Overview
- Founded
-
2011
- Status
-
Public
- Employees
-
14
- Stock Symbol
-
327610
- Share Price
-
$10.05
- (As of Friday Closing)
Femtobiomed General Information
Description
Femtobiomed Inc is a South Korea based company engaged in developing a cargo-free intracellular delivery platform called Cell Shot Platform. It is focused on using this technology to work on cell-based therapeutic pipelines.
Contact Information
Primary Industry
Biotechnology
Stock Exchange
KRX
Primary Office
- 17 Pangyoro-228-beon-gil
- Bundang-gu
- Seongnam-si, Gyeonggi-do
- South Korea
+82 000-000-0000
Femtobiomed Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $10.05 | $10.56 | $7.21 - $15.45 | $84.5M | 8.4M | 1.58K | -$0.97 |
Femtobiomed Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2021 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 124,939 | 124,939 | 89,342 | 45,048 |
| Revenue | 201 | 201 | 212 | 181 |
| EBITDA | (7,590) | (7,590) | (2,579) | (3,439) |
| Net Income | (8,151) | (8,151) | (3,024) | (3,901) |
| Total Assets | 3,851 | 3,851 | 2,105 | 4,341 |
| Total Debt | 301 | 301 | 562 | 309 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Femtobiomed Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Femtobiomed Patents
Femtobiomed Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3882332-A1 | Method and apparatus for controlling intracellular delivery of materials | Pending | 12-Nov-2018 | 000000000 | |
| EP-3882332-A4 | Method and apparatus for controlling intracellular delivery of materials | Pending | 12-Nov-2018 | 000000000 | 0 |
| JP-6799086-B2 | Method for quantifying hydrophobic components in liquid using contact surface diffusion coefficient and method for providing information for diagnosis of diseases using this method | Active | 26-Apr-2017 | 000000000 | |
| JP-2019521338-A | Method of quantifying hydrophobic component in liquid using contact surface diffusion coefficient and method of providing information for diagnosis of disease using the same | Active | 26-Apr-2017 | 000000000 | |
| US-20190032000-A1 | Device for putting material into cell | Inactive | 28-Dec-2014 | C12M35/02 | 0 |
Femtobiomed Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Sang-Hyun Lee Ph.D | Founder & Co-Chief Executive Officer |
Femtobiomed Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
